While Mitapivat also showed a reduction in the primary endpoint of annualized rate of sickle cell pain crises (SCPCs) compared to placebo, this trend did not achieve statistical significance, Agios said.
Read Full
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
